Literature DB >> 25568424

Does amputation offer any survival benefit over limb salvage in osteosarcoma patients with poor chemonecrosis and close margins?

K I A Reddy1, H Wafa2, C L Gaston3, R J Grimer3, A T Abudu3, L M Jeys3, S R Carter3, R M Tillman3.   

Abstract

A poor response to chemotherapy (≤ 90% necrosis) for osteosarcomas leads to poorer survival and an increased risk of local recurrence, particularly if there is a close margin of excision. We evaluated whether amputation confers any survival benefit over limb salvage surgery (LSS) with narrow margins in patients who respond poorly to chemotherapy. We only analysed patients with an osteosarcoma of the limb, a poor response to chemotherapy and close margins on LSS (marginal/intralesional) or primary amputation: 360 patients (36 LSS (intralesional margins), 197 LSS (marginal margins) and 127 amputations) were included. Local recurrence developed in 13 (36%) following LSS with intralesional margins, and 39 (20%) following LSS with marginal margins. There was no local recurrence in patients who underwent amputation. The five-year survival for all patients was 41% (95% confidence interval (CI) 35 to 46), but for those treated by LSS with marginal margins was 46.2% (95% CI 38 to 53), 36.3% (95% CI 27 to 45) for those treated by amputation, and 28% (95 CI 14 to 44) for those treated by LSS with intralesional margins. Patients who had LSS and then developed local recurrence as a first event had the same survival as those who had primary amputation without local recurrence. Prophylactic adjuvant radiotherapy was used in 40 patients but had no discernible effect in preventing local recurrence. Although amputation offered better local control, it conferred no clear survival benefit over LSS with marginal margins in these patients with a poor overall prognosis. ©2015 The British Editorial Society of Bone & Joint Surgery.

Entities:  

Keywords:  Osteosarcoma; Poor chemonecrosis; Amputation; Limb salvage; Margins; Prognosis; Local recurrence

Mesh:

Year:  2015        PMID: 25568424     DOI: 10.1302/0301-620X.97B1.33924

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  25 in total

1.  MRI Identification of the Osseous Extent of Pediatric Bone Sarcomas.

Authors:  Matthew J Thompson; John C Shapton; Stephanie E Punt; Christopher N Johnson; Ernest U Conrad
Journal:  Clin Orthop Relat Res       Date:  2018-03       Impact factor: 4.176

2.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17

3.  Impact of Limb Salvage on Prognosis of Patients Diagnosed With Extremity Bone and Soft Tissue Sarcomas.

Authors:  Kaixu Yu; Ying Chen; Kehan Song; Fanxiu Xiong; Yahao Tian; Hanfeng Guan; Feng Li
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

4.  A Novel System for the Surgical Staging of Primary High-grade Osteosarcoma: The Birmingham Classification.

Authors:  Lee M Jeys; Chris J Thorne; Michael Parry; Czar Louie L Gaston; Vaiyapuri P Sumathi; J Robert Grimer
Journal:  Clin Orthop Relat Res       Date:  2017-03       Impact factor: 4.176

Review 5.  Amputation Versus Limb-Salvage Surgery in Patients with Osteosarcoma: A Meta-analysis.

Authors:  Gang Han; Wen-Zhi Bi; Meng Xu; Jin-Peng Jia; Yan Wang
Journal:  World J Surg       Date:  2016-08       Impact factor: 3.352

6.  Factors Affecting Prognosis and Survival in Extremity Osteosarcoma.

Authors:  Anvesh Dharanikota; Ravi Arjunan; Ashwathappa Dasappa
Journal:  Indian J Surg Oncol       Date:  2021-01-06

7.  Prophylactic antibiotic regimens in tumour surgery (PARITY): a pilot multicentre randomised controlled trial.

Authors: 
Journal:  Bone Joint Res       Date:  2015-09       Impact factor: 5.853

8.  Transition from Tumor Tissue to Bone Marrow in Patients with Appendicular Osteosarcoma after Neoadjuvant Chemotherapy.

Authors:  Zhi-Ping Deng; Bao-Yue Liu; Yang Sun; Tao Jin; Bin Li; Yi Ding; Xiao-Hui Niu
Journal:  Chin Med J (Engl)       Date:  2017-09-20       Impact factor: 2.628

9.  Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS).

Authors:  Andrés Redondo; Silvia Bagué; Daniel Bernabeu; Eduardo Ortiz-Cruz; Claudia Valverde; Rosa Alvarez; Javier Martinez-Trufero; Jose A Lopez-Martin; Raquel Correa; Josefina Cruz; Antonio Lopez-Pousa; Aurelio Santos; Xavier García Del Muro; Javier Martin-Broto
Journal:  Cancer Chemother Pharmacol       Date:  2017-10-16       Impact factor: 3.333

Review 10.  UK guidelines for the management of bone sarcomas.

Authors:  Craig Gerrand; Nick Athanasou; Bernadette Brennan; Robert Grimer; Ian Judson; Bruce Morland; David Peake; Beatrice Seddon; Jeremy Whelan
Journal:  Clin Sarcoma Res       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.